Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy

Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, with a five-year survival rate below 15 %. Claudin 18.2 (CLDN18.2) has emerged as a novel potential therapeutic target in PDAC. Zolbetuximab, a monoclonal antibody targeting CLDN18.2, has demonstrated therapeutic benefit in gastric cance...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Riley J. Arseneau, Emma Kempster, Carley Bekkers, Thomas Samson, Boris L. Gala-Lopez, Ravi Ramjeesingh, Jeanette E. Boudreau, Thomas Arnason
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2025-05-01
Rangatū:	Translational Oncology
Ngā marau:	Pancreatic ductal carcinoma Immunohistochemistry Claudin 18 protein, human Biomarkers 43–14a zolbetuximab
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S1936523325000932
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!